Abacavir And Lamivudine Tablet, Film Coated
Product Images NDC 65862-335

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Abacavir And Lamivudine (NDC 65862-335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Package Label-principal Display Panel – 600 mg/300 mg (30 Tablets Container) (Abalami Fig1)

Package Label-principal Display Panel – 600 mg/300 mg (30 Tablets Container) (Abalami Fig1)
This is a description of a medicine named Abacavir and Lamivudine Tablets USP which includes 600 mg of abacavir and 300 mg of lamivudine. Each tablet is film-coated and contains FD&C Yellow No.6 color additive in it. The usual dosage information is not available; however, it is advised to see the prescribing information for dosage and administration. The medication is distributed by Aurabindo Pharma USA, Inc. and the batch code is TS/DRUGS/19/1993. The tablets should be stored at room temperature within 15-30°C (59° to 86°F). Each time the tablets are dispensed, it is important to give the patient a Medication Guide and Warning Card from the carton.*
FDA Label Image

Package Label-principal Display Panel – 600 mg/300 mg (30 Tablets Container Carton) (Abalami Fig2)

Package Label-principal Display Panel – 600 mg/300 mg (30 Tablets Container Carton) (Abalami Fig2)
Abacavir and Lamivudine tablets are a prescription medicine used to treat HIV-1 infection. This medication contains Abacavir sulfate USP equivalent to abacavir 600 mg and lamivudine USP 300 mg. It is advised to read the prescribing information before using the medicine. The tablets should be stored at 20-25°C with excursions permitted to 15-30°C. The medication should be given with a medication guide and warning card from the carton. Distributed by Aurobindo Pharma USA, Inc.*
FDA Label Image

Package Label-principal Display Panel – 600 mg/300 mg (100 Unit-dose Tablets (10 X 10s)) (Abalami Fig3)

Package Label-principal Display Panel – 600 mg/300 mg (100 Unit-dose Tablets (10 X 10s)) (Abalami Fig3)
Abacavir and Lamivudine Tablets USP containing Abacavir sulfate USP equivalent to abacavir 600 mg and lamivudine USP 300 mg in each film-coated tablet are available as 100 unit-dose tablets (10 x 10s). These tablets are meant for oral administration and are distributed by Aurobindo Pharma USA, Inc. Each time Abacavir and Lamivudine Tablets USP are dispensed, the patient must be given a Medication Guide and Warning Card from the carton. The usual dosage for these tablets is mentioned in the prescribing information that comes with the tablets. The tablets contain FD&C Yellow No. 6 as a color additive and must be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° t0 30°C (59° to 86°F) [see USP Controlled Room Temperature]. The given text does not have a clear context and can be used as a general description of Abacavir and Lamivudine Tablets USP.*
FDA Label Image

Abacavir Sulfate Structure (Abalami Str1)

Abacavir Sulfate Structure (Abalami Str1)
FDA Label Image

Lamivudine Structure (Abalami Str2)

Lamivudine Structure (Abalami Str2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.